Clinical Trial

A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)

Name: A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR) — clinical trial record (NCT07557446)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: EIR

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is to evaluate the safety and efficacy of AGA2115 at three different dose regimens in Chinese adults and adolescents with Type I, III, or IV Osteogenesis imperfecta (OI).

Protocol Amendment History 1 change

critical Recruitment opened 2026-06-23

Trial Details

NCT Number	NCT07557446
Lead Sponsor	Angitia Biopharmaceuticals Guangzhou Limited
Conditions	Osteogenesis Imperfecta (OI)
Enrollment	48 participants
Start Date	2026-06
Primary Completion	2028-04 (estimated)
Study Completion	2029-07 (estimated)
Updated on ClinicalTrials.gov	2026-06-22